172 related articles for article (PubMed ID: 26862847)
1. Clinical response to azacitidine therapy depends on microRNA-29c (miR-29c) expression in older acute myeloid leukemia (AML) patients.
Butrym A; Rybka J; Baczyńska D; Poręba R; Kuliczkowski K; Mazur G
Oncotarget; 2016 May; 7(21):30250-7. PubMed ID: 26862847
[TBL] [Abstract][Full Text] [Related]
2. The clinical characteristics and prognostic significance of MN1 gene and MN1-associated microRNA expression in adult patients with de novo acute myeloid leukemia.
Xiang L; Li M; Liu Y; Cen J; Chen Z; Zhen X; Xie X; Cao X; Gu W
Ann Hematol; 2013 Aug; 92(8):1063-9. PubMed ID: 23515710
[TBL] [Abstract][Full Text] [Related]
3. Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients.
Butrym A; Rybka J; Baczyńska D; Tukiendorf A; Kuliczkowski K; Mazur G
Biomark Med; 2015; 9(5):453-60. PubMed ID: 25620533
[TBL] [Abstract][Full Text] [Related]
4. Expression of microRNA-181 determines response to treatment with azacitidine and predicts survival in elderly patients with acute myeloid leukaemia.
Butrym A; Rybka J; Baczyńska D; Poręba R; Mazur G; Kuliczkowski K
Oncol Lett; 2016 Oct; 12(4):2296-2300. PubMed ID: 27698792
[TBL] [Abstract][Full Text] [Related]
5. Low expression of microRNA-204 (miR-204) is associated with poor clinical outcome of acute myeloid leukemia (AML) patients.
Butrym A; Rybka J; Baczyńska D; Tukiendorf A; Kuliczkowski K; Mazur G
J Exp Clin Cancer Res; 2015 Jul; 34(1):68. PubMed ID: 26126974
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.
Quintás-Cardama A; Ravandi F; Liu-Dumlao T; Brandt M; Faderl S; Pierce S; Borthakur G; Garcia-Manero G; Cortes J; Kantarjian H
Blood; 2012 Dec; 120(24):4840-5. PubMed ID: 23071272
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
van der Helm LH; Veeger NJ; Kooy Mv; Beeker A; de Weerdt O; de Groot M; Alhan C; Hoogendoorn M; Laterveer L; van de Loosdrecht AA; Koedam J; Vellenga E; Huls G
Leuk Res; 2013 Aug; 37(8):877-82. PubMed ID: 23628552
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens.
Seymour JF; Döhner H; Butrym A; Wierzbowska A; Selleslag D; Jang JH; Kumar R; Cavenagh J; Schuh AC; Candoni A; Récher C; Sandhu I; Del Castillo TB; Al-Ali HK; Falantes J; Stone RM; Minden MD; Weaver J; Songer S; Beach CL; Dombret H
BMC Cancer; 2017 Dec; 17(1):852. PubMed ID: 29241450
[TBL] [Abstract][Full Text] [Related]
9. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
[TBL] [Abstract][Full Text] [Related]
10. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Pollyea DA; Zehnder J; Coutre S; Gotlib JR; Gallegos L; Abdel-Wahab O; Greenberg P; Zhang B; Liedtke M; Berube C; Levine R; Mitchell BS; Medeiros BC
Haematologica; 2013 Apr; 98(4):591-6. PubMed ID: 23242596
[TBL] [Abstract][Full Text] [Related]
11. miR-29c&b2 encourage extramedullary infiltration resulting in the poor prognosis of acute myeloid leukemia.
Wei Y; Lu W; Yu Y; Zhai Y; Guo H; Yang S; Zhao C; Zhang Y; Liu J; Liu Y; Fei J; Shi J
Oncogene; 2021 May; 40(19):3434-3448. PubMed ID: 33888868
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of miR-29c is a prognostic biomarker in acute myeloid leukemia and can reduce the sensitivity of leukemic cells to decitabine.
Tang LJ; Sun GK; Zhang TJ; Wu DH; Zhou JD; Ma BB; Xu ZJ; Wen XM; Chen Q; Yao DM; Qian J; Ma JC; Lin J
Cancer Cell Int; 2019; 19():177. PubMed ID: 31333331
[TBL] [Abstract][Full Text] [Related]
14. A novel miR-375-HOXB3-CDCA3/DNMT3B regulatory circuitry contributes to leukemogenesis in acute myeloid leukemia.
Bi L; Zhou B; Li H; He L; Wang C; Wang Z; Zhu L; Chen M; Gao S
BMC Cancer; 2018 Feb; 18(1):182. PubMed ID: 29439669
[TBL] [Abstract][Full Text] [Related]
15. Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia.
Zhang TJ; Wang YX; Yang DQ; Yao DM; Yang L; Zhou JD; Deng ZQ; Wen XM; Guo H; Ma JC; Lin J; Qian J
Clin Lab; 2016; 62(1-2):113-20. PubMed ID: 27012040
[TBL] [Abstract][Full Text] [Related]
16. MN1, FOXP1 and hsa-miR-181a-5p as prognostic markers in acute myeloid leukemia patients treated with intensive induction chemotherapy and autologous stem cell transplantation.
Seipel K; Messerli C; Wiedemann G; Bacher U; Pabst T
Leuk Res; 2020 Feb; 89():106296. PubMed ID: 31927137
[TBL] [Abstract][Full Text] [Related]
17. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
[TBL] [Abstract][Full Text] [Related]
18. Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Thépot S; Itzykson R; Seegers V; Recher C; Raffoux E; Quesnel B; Delaunay J; Cluzeau T; Marfaing Koka A; Stamatoullas A; Chaury MP; Dartigeas C; Cheze S; Banos A; Morel P; Plantier I; Taksin AL; Marolleau JP; Pautas C; Thomas X; Isnard F; Beve B; Chait Y; Guerci A; Vey N; Dreyfus F; Ades L; Ifrah N; Dombret H; Fenaux P; Gardin C;
Am J Hematol; 2014 Apr; 89(4):410-6. PubMed ID: 24375487
[TBL] [Abstract][Full Text] [Related]
19. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia.
Tang X; Chen L; Yan X; Li Y; Xiong Y; Zhou X
Med Sci Monit; 2015 Nov; 21():3427-33. PubMed ID: 26549593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
